| scholarly article | Q13442814 |
| review article | Q7318358 |
| P6179 | Dimensions Publication ID | 1031549590 |
| P356 | DOI | 10.1007/S11914-016-0332-1 |
| P3181 | OpenCitations bibliographic resource ID | 3155972 |
| P932 | PMC publication ID | 5104767 |
| P698 | PubMed publication ID | 27704396 |
| P2093 | author name string | Masahiro Yamamoto | |
| Toshitsugu Sugimoto | |||
| P2860 | cites work | Contribution of collagen and mineral to the elastic-plastic properties of bone | Q22330868 |
| Development and prevention of advanced diabetic nephropathy in RAGE-overexpressing mice | Q28344139 | ||
| Age-related changes in the collagen network and toughness of bone | Q44058103 | ||
| Effect of alendronate on bone mineral density and biochemical markers of bone turnover in type 2 diabetic women: the fracture intervention trial | Q44456942 | ||
| Associations between baseline risk factors and vertebral fracture risk in the Multiple Outcomes of Raloxifene Evaluation (MORE) Study | Q44833348 | ||
| Diabetes mellitus and the incidence of hip fracture: results from the Nord-Trøndelag Health Survey | Q45058945 | ||
| Mechanisms of maturation and ageing of collagen | Q45345441 | ||
| Sex differences in osteoporosis in older adults with non-insulin-dependent diabetes mellitus | Q45937461 | ||
| Raloxifene ameliorates detrimental enzymatic and nonenzymatic collagen cross-links and bone strength in rabbits with hyperhomocysteinemia. | Q45988732 | ||
| Collagen maturity, glycation induced-pentosidine, and mineralization are increased following 3-year treatment with incadronate in dogs | Q46277861 | ||
| Degree of mineralization-related collagen crosslinking in the femoral neck cancellous bone in cases of hip fracture and controls | Q46281109 | ||
| Reductions in degree of mineralization and enzymatic collagen cross-links and increases in glycation-induced pentosidine in the femoral neck cortex in cases of femoral neck fracture | Q46282165 | ||
| Effects of preexisting microdamage, collagen cross-links, degree of mineralization, age, and architecture on compressive mechanical properties of elderly human vertebral trabecular bone | Q46295396 | ||
| Older women with diabetes have an increased risk of fracture: a prospective study | Q46556380 | ||
| Autophagy protects osteoblasts from advanced glycation end products-induced apoptosis through intracellular reactive oxygen species | Q46591928 | ||
| Advanced glycation end products and bone loss during aging. | Q46613220 | ||
| Serum pentosidine levels are positively associated with the presence of vertebral fractures in postmenopausal women with type 2 diabetes | Q46832348 | ||
| Bone Formation is Affected by Matrix Advanced Glycation End Products (AGEs) In Vivo. | Q51311945 | ||
| Changes in the contents of enzymatic immature, mature, and non-enzymatic senescent cross-links of collagen after once-weekly treatment with human parathyroid hormone (1-34) for 18 months contribute to improvement of bone strength in ovariectomized m | Q51536719 | ||
| Advanced glycation end products affect growth and function of osteoblasts. | Q54349806 | ||
| Bone Density in Non-Insulin-Dependent Diabetes Mellitus: The Rotterdam Study | Q57388854 | ||
| TBS (Trabecular Bone Score) and Diabetes-Related Fracture Risk | Q57711458 | ||
| Consensus development conference: prophylaxis and treatment of osteoporosis | Q68180978 | ||
| Effects of high concentrations of glucose on PTH secretion in parathyroid cells | Q68521891 | ||
| Bone mineral density in women with type II diabetes mellitus | Q69606688 | ||
| Bone mineral density measured by dual energy x-ray absorptiometry in patients with non-insulin-dependent diabetes mellitus | Q70584765 | ||
| Osteopenia in insulin-dependent diabetes mellitus; prevalence and aspects of pathophysiology | Q73958624 | ||
| Intensive insulin therapy and bone mineral density in type 1 diabetes mellitus: a prospective study | Q74060645 | ||
| Type 1 and type 2 diabetes and incident hip fractures in postmenopausal women | Q74086478 | ||
| Bone mineral density in patients with type 1 and type 2 diabetes | Q77945576 | ||
| Differential expression of human lysyl hydroxylase genes, lysine hydroxylation, and cross-linking of type I collagen during osteoblastic differentiation in vitro | Q78157858 | ||
| Contribution of the advanced glycation end product pentosidine and of maturation of type I collagen to compressive biomechanical properties of human lumbar vertebrae | Q79863234 | ||
| Regulation of advanced glycation end product (AGE) receptors and apoptosis by AGEs in osteoblast-like cells | Q80695166 | ||
| Diabetic patients have an increased risk of vertebral fractures independent of BMD or diabetic complications | Q82803173 | ||
| Decreased PTH levels accompanied by low bone formation are associated with vertebral fractures in postmenopausal women with type 2 diabetes | Q83455687 | ||
| Type 2 diabetes mellitus in nursing home patients: effects on bone turnover, bone mass, and fracture risk | Q83877141 | ||
| Role of collagen enzymatic and glycation induced cross-links as a determinant of bone quality in spontaneously diabetic WBN/Kob rats | Q83979831 | ||
| Advanced glycation end products (AGEs), but not high glucose, inhibit the osteoblastic differentiation of mouse stromal ST2 cells through the suppression of osterix expression, and inhibit cell growth and increasing cell apoptosis | Q84823342 | ||
| High serum pentosidine but not esRAGE is associated with prevalent fractures in type 1 diabetes independent of bone mineral density and glycaemic control | Q87406239 | ||
| Heterogeneous glycation of cancellous bone and its association with bone quality and fragility | Q28482286 | ||
| Advanced Glycation Endproducts and Bone Material Properties in Type 1 Diabetic Mice | Q28551744 | ||
| N(epsilon)-(carboxymethyl)lysine adducts of proteins are ligands for receptor for advanced glycation end products that activate cell signaling pathways and modulate gene expression | Q28645594 | ||
| Age-related factors affecting the postyield energy dissipation of human cortical bone | Q30501027 | ||
| In situ accumulation of advanced glycation endproducts (AGEs) in bone matrix and its correlation with osteoclastic bone resorption | Q33885263 | ||
| Osteoporosis prevention, diagnosis, and therapy | Q34140339 | ||
| High-resolution peripheral quantitative computed tomographic imaging of cortical and trabecular bone microarchitecture in patients with type 2 diabetes mellitus | Q34262412 | ||
| Structure elucidation of a senescence cross-link from human extracellular matrix. Implication of pentoses in the aging process | Q34663994 | ||
| Age-related effect on the concentration of collagen crosslinks in human osteonal and interstitial bone tissue. | Q35741491 | ||
| Association of BMD and FRAX score with risk of fracture in older adults with type 2 diabetes | Q35780843 | ||
| Trabecular microfracture and the influence of pyridinium and non-enzymatic glycation-mediated collagen cross-links | Q35809570 | ||
| Maillard reaction-mediated molecular damage to extracellular matrix and other tissue proteins in diabetes, aging, and uremia | Q35840907 | ||
| Advanced glycation end products stimulate osteoblast apoptosis via the MAP kinase and cytosolic apoptotic pathways. | Q35878806 | ||
| Circulating levels of carboxy‐methyl‐lysine (CML) are associated with hip fracture risk: the Cardiovascular Health Study | Q35911173 | ||
| Bone quality: understanding what matters | Q35991871 | ||
| Osteoporosis in type II diabetes | Q36457241 | ||
| Increased cortical porosity in type 2 diabetic postmenopausal women with fragility fractures. | Q36501319 | ||
| Discrepancies in bone mineral density and fracture risk in patients with type 1 and type 2 diabetes--a meta-analysis | Q36636165 | ||
| Systematic review of type 1 and type 2 diabetes mellitus and risk of fracture | Q36851830 | ||
| Nonenzymatic Glycation and Degree of Mineralization Are Higher in Bone From Fractured Patients With Type 1 Diabetes Mellitus. | Q36924625 | ||
| Advanced Glycation Endproducts and Bone Material Strength in Type 2 Diabetes. | Q36965274 | ||
| Clinical review: The role of advanced glycation end products in progression and complications of diabetes | Q37053328 | ||
| Pentosidine and increased fracture risk in older adults with type 2 diabetes | Q37257534 | ||
| Changes in non-enzymatic glycation and its association with altered mechanical properties following 1-year treatment with risedronate or alendronate. | Q37323596 | ||
| Low serum level of the endogenous secretory receptor for advanced glycation end products (esRAGE) is a risk factor for prevalent vertebral fractures independent of bone mineral density in patients with type 2 diabetes | Q37437155 | ||
| Bone quality and osteoporosis therapy | Q37756589 | ||
| Novel splice variants of the receptor for advanced glycation end-products expressed in human vascular endothelial cells and pericytes, and their putative roles in diabetes-induced vascular injury | Q38359414 | ||
| Non-enzymatic glycation of bone collagen modifies osteoclastic activity and differentiation. | Q38700889 | ||
| Effects of high glucose and advanced glycation end products on the expressions of sclerostin and RANKL as well as apoptosis in osteocyte-like MLO-Y4-A2 cells | Q38905639 | ||
| Advanced glycation end product 3 (AGE3) suppresses the mineralization of mouse stromal ST2 cells and human mesenchymal stem cells by increasing TGF-β expression and secretion | Q39001756 | ||
| The combination of high glucose and advanced glycation end-products (AGEs) inhibits the mineralization of osteoblastic MC3T3-E1 cells through glucose-induced increase in the receptor for AGEs | Q40062475 | ||
| Cross-linking in collagen and elastin | Q40095161 | ||
| Advanced glycation end-products attenuate human mesenchymal stem cells and prevent cognate differentiation into adipose tissue, cartilage, and bone | Q40390871 | ||
| Teriparatide in patients with osteoporosis and type 2 diabetes | Q40669221 | ||
| Effect of advanced glycation endproducts on the secretion of insulin-like growth factor-I and its binding proteins: role in osteoblast development | Q40752871 | ||
| Role of advanced glycation end products in adynamic bone disease in patients with diabetic nephropathy. | Q40778071 | ||
| Influence of cross-link structure, density and mechanical properties in the mesoscale deformation mechanisms of collagen fibrils | Q41778121 | ||
| Bone mineral density at time of clinical diagnosis of adult-onset type 1 diabetes mellitus | Q42510908 | ||
| P275 | copyright license | Creative Commons Attribution 4.0 International | Q20007257 |
| P6216 | copyright status | copyrighted | Q50423863 |
| P433 | issue | 6 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | diabetes | Q12206 |
| membrane protein | Q423042 | ||
| tissue | Q40397 | ||
| human musculoskeletal system | Q726543 | ||
| cell surface receptor | Q2476074 | ||
| protein degradation end products | Q78445543 | ||
| P5008 | on focus list of Wikimedia project | ScienceSource | Q55439927 |
| P304 | page(s) | 320-326 | |
| P577 | publication date | 2016-12-01 | |
| P1433 | published in | Current osteoporosis reports | Q26841869 |
| P1476 | title | Advanced Glycation End Products, Diabetes, and Bone Strength | |
| P478 | volume | 14 |
| Q90599010 | Alarmins in Osteoporosis, RAGE, IL-1, and IL-33 Pathways: A Literature Review |
| Q90267329 | Blockade of receptors of advanced glycation end products ameliorates diabetic osteogenesis of adipose-derived stem cells through DNA methylation and Wnt signalling pathway |
| Q50000597 | Contributions of material properties and structure to increased bone fragility for a given bone mass in the UCD-T2DM rat model of type 2 diabetes |
| Q47746131 | Correlates of Calcaneal Quantitative Ultrasound Parameters in Patients with Diabetes: The Study on the Assessment of Determinants of Muscle and Bone Strength Abnormalities in Diabetes |
| Q99238223 | Current Knowledge Regarding the Interaction Between Oral Bone Metabolic Disorders and Diabetes Mellitus |
| Q93364919 | Diabetes pharmacotherapy and effects on the musculoskeletal system |
| Q47147079 | Exenatide Improves Bone Quality in a Murine Model of Genetically Inherited Type 2 Diabetes Mellitus |
| Q90265184 | High Glucose Level Impairs Human Mature Bone Marrow Adipocyte Function Through Increased ROS Production |
| Q61806044 | Hyponatremia Is Associated With Increased Osteoporosis and Bone Fractures in Patients With Diabetes With Matched Glycemic Control |
| Q91329973 | In vivo Labeling of Bone Microdamage in an Animal Model of Type 1 Diabetes Mellitus |
| Q39007288 | Is Diabetic Skeletal Fragility Associated with Microvascular Complications in Bone? |
| Q92283270 | Non-invasive skin autofluorescence, blood and urine assays of the advanced glycation end product (AGE) pentosidine as an indirect indicator of AGE content in human bone |
| Q53703048 | Obesity, Metabolic Syndrome, and Musculoskeletal Disease: Common Inflammatory Pathways Suggest a Central Role for Loss of Muscle Integrity. |
| Q58766909 | Skeletal Status, Body Composition, and Glycaemic Control in Adolescents with Type 1 Diabetes Mellitus |
| Q50098430 | Urinary Pentosidine levels negatively associates with trabecular bone scores in patients with type 2 diabetes mellitus |
| Q47855337 | Weak bones in diabetes mellitus - an update on pharmaceutical treatment options |
Search more.